

eCommons@AKU

Department of Radiation Oncology

Medical College, Pakistan

January 2012

Cisplatin-induced posterior reversible encephalopathy syndrome and successful retreatment in a patient with non-seminomatous germ cell tumor: a case report

Muhammad Nauman Zahir Aga Khan University

Nehal Masood Aga Khan University, nehal.masood@aku.edu

Munira Shabbir-Moosajee

Aga Khan University, munira.moosajee@aku.edu

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_radiat_oncol
Part of the Oncology Commons, and the Radiation Medicine Commons

Recommended Citation

Zahir, M. N., Masood, N., Shabbir-Moosajee, M. (2012). Cisplatin-induced posterior reversible encephalopathy syndrome and successful re-treatment in a patient with non-seminomatous germ cell tumor: a case report. *Journal of Medical Case Reports*, 6, 409. **Available at:** https://ecommons.aku.edu/pakistan_fhs_mc_radiat_oncol/37



CASE REPORT Open Access

Cisplatin-induced posterior reversible encephalopathy syndrome and successful re-treatment in a patient with non-seminomatous germ cell tumor: a case report

Muhammad Nauman Zahir*, Nehal Masood and Munira Shabbir-Moosajee

Abstract

Introduction: Cisplatin is a platinum compound that has revolutionized the treatment of various solid organ tumors. Cisplatin is associated with a variety of side effects and has recently been indicted in the development of posterior reversible encephalopathy syndrome. Posterior reversible encephalopathy syndrome is a potentially reversible condition, with the mainstay of therapy being correction of the underlying cause and withdrawal of the offending drug. However, there are no clear guidelines regarding the possibility of subsequent re-treatment with the causative agent.

Case presentation: A 23-year-old Asian man presented to our Emergency Department with a four-month history of concomitant abdominal pain and backache and a two-week history of left-sided leg swelling. Diagnostic investigations revealed bilateral pulmonary embolism, extensive deep venous thrombosis and widespread lung and liver metastatic deposits with abdomino-pelvic lymphadenopathy. His biopsy and tumor markers were consistent with non-seminomatous germ cell tumor and he was subsequently started on an initial cycle of cisplatin and etoposide chemotherapy. On the second day of treatment he developed posterior reversible encephalopathy syndrome clinically and radiologically. Cisplatin was stopped for the next two days while etoposide was continued, resulting in complete resolution of his symptoms. He was re-challenged with cisplatin on day five of chemotherapy because a platin-based chemotherapy regimen was his only hope of potential cure. He tolerated it well, with no recurrence of his neurological symptoms and the remainder of his in-patient stay remained uneventful. He was discharged on day eight. He has since then completed treatment and is currently in remission.

Conclusions: The occurrence of posterior reversible encephalopathy syndrome after cisplatin use has been well reported in the literature. We strongly believe that our patient also developed posterior reversible encephalopathy syndrome secondary to cisplatin. The uniqueness of our patient's case lies in the successful re-treatment of our patient with the offending drug. To the best of our knowledge, this is the first instance where a patient was successfully re-treated with cisplatin after having developed posterior reversible encephalopathy syndrome as a result of cisplatin use. The excellent response to re-treatment without recurrence of neurological symptoms in our patient's case provides insight into re-treatment as an option in scenarios where treatment options are limited.

Keywords: Cisplatin, PRES, Re-treatment

^{*} Correspondence: nauman.zahir@aku.edu Department of Medicine, Division of Hematology and Oncology, Aga Khan University Hospital, Stadium Road, PO BOX: 3500, Karachi 74800, Pakistan



Introduction

Cisplatin is a platinum compound which has revolutionized the treatment of various solid organ tumors and since its introduction in the 1970s has become the backbone of many chemotherapeutic regimens. Cisplatin is associated with a variety of side effects, the most common being nausea, vomiting, nephrotoxicity, ototoxicity and neurotoxicity [1]. The neurotoxicity usually manifests in the form of an axonal sensory neuropathy as peripheral nerves are exposed to the highest levels of cisplatin with resultant deposition of metal metabolites in these nerves [2]. Central nervous system (CNS) neurotoxicity of cisplatin is rare, but has been well documented in the medical literature. An array of CNS disorders including seizures, hemiparesis, cortical blindness, aphasia and coma have been attributed to cisplatin therapy [3]. Recently, cisplatin has been reported to cause posterior reversible encephalopathy syndrome (PRES).

PRES is a clinico-radiological entity characterized by the onset of a variety of neurological manifestations associated with transient changes typically in the posterior circulation of the brain [2]. The commonly associated neurological symptoms include headache, seizures, confusion and visual disturbances. The exact pathogenesis of PRES remains unclear; however, two factors are known to predispose patients to the development of PRES: disordered cerebral autoregulation and endothelial damage. PRES secondary to cytotoxic chemotherapy is thought to be precipitated by the direct toxic effect of the drug on the cerebral vascular endothelium. Endothelial damage results in capillary leakage, disruption of the blood brain barrier, axonal swelling and development of vasogenic edema, which is a hallmark feature of PRES. Vasogenic edema and autoregulatory failure of the cerebral circulation in turn can lead to a decrease in cerebral perfusion which results in the clinical manifestations of PRES [4,5]. Clinically, it is characterized by subacute development of headache, seizures, confusion and visual disturbance and occasionally hypertensive crisis [2]. These symptoms occur as a result of vasogenic edema in the parietal and occipital lobes, which are preferentially involved [4].

Radiographically, PRES presents on magnetic resonance imaging (MRI) scans as edema symmetrically affecting the subcortical white matter most commonly in the posterior cerebral hemispheres. It is important to note, however, that any region of the CNS can be affected [5,6]. The most common MRI abnormality is punctate or confluent areas of increased signal on proton density and T2-weighted and fluid attenuated inversion recovery (FLAIR) images. Additional MRI features can include gyriform signal enhancement following the administration of gadolinium, petechial and large parenchymal hemorrhages, hypo or iso-intense signal on diffusion weighted imaging and increased signal on apparent diffusion coefficient (ADC) maps [7].

A wide variety of medical conditions have been implicated with PRES. The more frequently reported association is with hypertensive encephalopathy, eclampsia and use of immunosuppressive drugs [5]. Various cytotoxic, immunosuppressive and biological agents including cisplatin have been indicted in the development of PRES [8]. PRES, as the name suggests, is a potentially reversible condition, with the fundamental step in treatment being correction of the underlying cause and withdrawal of the offending drug. However, there are no clear guidelines on the possibility of re-treatment with the causative agent.

Case presentation

We report the case of a 23-year-old Asian man who presented to our Emergency Department (ED) with a four-month history of concomitant abdominal pain and backache and a two-week history of left-sided leg swelling. An abdominal ultrasonogram performed for his complaints revealed a soft tissue mass involving the prostate, abutting the anterior rectal wall and the urinary bladder along with significant para-aortic lymphadenopathy.

He was in respiratory distress on presentation to the ED. Further investigation showed bilateral pulmonary embolism due to extensive deep venous thrombosis (DVT) involving both lower limbs and extending up to the inferior vena cava (IVC) for which low-molecular-weight heparin (LMWH) was initiated. Computed tomography (CT) scans additionally revealed extensive lung and liver metastatic deposits along with conglomerate abdominopelvic lymphadenopathy. An ultrasonogram of the testes was negative for any intra-testicular or extra-testicular mass lesion. Given his relatively young age at presentation, a retro-peritoneal germ cell tumor was suspected.

The serum lactate dehydrogenase (LDH), α -fetoprotein (AFP) and β -human chorionic gonadotropin (β -HCG) levels were 7596IU/L, 88.5IU/mL and 21,753mIU/mL, respectively. Biopsy of the abdominal adenopathy was consistent with a non-seminomatous germ cell tumor with a prominent yolk sac tumor component. Pulmonary function tests with diffusing capacity of the lung for carbon monoxide (DLCO) were performed, which revealed the DLCO to be only 46 percent of the predicted value.

Our patient was established as having a stage IIIC (poor risk) non-seminomatous germ cell tumor and was subsequently started on cisplatin (20mg/m² on days one to five) and etoposide (100mg/m² on days one to five). Bleomycin was omitted from the regimen due to the poor DLCO. On the evening of day two of chemotherapy, he started having hypertensive episodes with systolic blood pressures ranging from 150 to 170mmHg and diastolic pressures in the range of 100 to 110mmHg. Within a few hours, he developed a tonic clonic seizure that was aborted by intravenous diazepam. He was also started on calcium channel blockers for management of hypertension. He then started to complain

of persistent blurring of vision once fully conscious from the post-ictal phase. His pupillary reflexes and fundoscopy were normal. A neurological examination revealed hyperreflexia of the lower limbs. Investigations excluded a metabolic abnormality as the cause of seizure. An MRI scan of the brain showed multiple abnormal signal intensity areas involving the peri-ventricular, posterior parietal and occipital regions bilaterally which were hyperintense on T2weighted images, hypointense on T1-weighted images and showed patchy post-contrast enhancement with no diffusion restriction (Figure 1). The findings were reported to be consistent with PRES. Cisplatin was withheld for the next two days as it was thought to be the most probable cause of PRES, and chemotherapy with single agent etoposide was continued. At 48 hours after the seizure and the withdrawal of cisplatin, our patient was significantly better with no further seizure episodes and almost complete resolution of his visual symptoms. His blood pressure had also been controlled with anti-hypertensive medications.

At this point we decided to resume cisplatin, because a platinum-based regimen was his only hope of potential cure. Under close surveillance, our patient was re-challenged with cisplatin at 20mg/m² on day five of chemotherapy. He tolerated it well with no recurrence of neurological symptoms, and the remainder of his in-patient stay remained uneventful. He was discharged on day eight of chemotherapy with complete resolution of symptoms.

He then went on to complete three additional cycles of cisplatin and etoposide with no dose reductions, with no further neurological complications. An interim analysis of disease response after two cycles was significant for normalization of LDH and β -HCG levels and a greater than 95 percent decline in AFP. CT scans showed significant improvement in disease process. Results of a brain MRI scan performed at the same time as this follow up were normal (Figure 2).

Post-treatment CT scans showed complete resolution of his liver and lung lesions but a residual retro-peritoneal nodal mass. Tumor markers (LDH, AFP and β -HCG) had all returned to within normal limits. As per international guidelines, he subsequently underwent resection of the residual nodal mass. Pathology was consistent with




Figure 1 Posterior reversible encephalopathy syndrome after cisplatin treatment. Bilateral and symmetrical abnormal intensity areas are identified in the occipital lobes involving the cortical and subcortical locations. These are hypointense on T1-weighted images **(A)** and hyperintense on T2-weighted images **(B)**, showing minimal patchy post-contrast enhancement **(C)** with no diffusion restriction **(D)**.

fibrocollagenous tissue exhibiting extensive fibrosis, but no viable tumor.

He is currently 90 days post-surgery and has recovered well. Post-operative scans show no evidence of disease. His tumor markers continue to remain within normal limits.

Conclusions

In the cases of PRES due to cisplatin reported to date, development of the syndrome led to discontinuation of cisplatin with resultant resolution of the symptoms. We strongly believe that our patient also developed PRES secondary to cisplatin. The fact that his symptoms resolved completely after withdrawal of cisplatin despite continuation of etoposide, which was the only other chemotherapeutic drug in the regimen, led us to this conclusion.

The uniqueness of our case does not lie in the development of PRES secondary to cisplatin use, but rather in the successful re-treatment of our patient with the offending drug once the acute symptomatology had subsided. The decision to re-treat with cisplatin was

taken because platinum based regimens form the backbone of treatment of germ cell tumors. It was decided that in our patient's case permanent withdrawal of cisplatin from the regimen would severely compromise our efforts of effectively treating a potentially curable malignancy. Carboplatin could have been used as an alternative to cisplatin for further treatment, but has been shown to be inferior in efficacy to the former [9] and was hence not contemplated.

To the best of our knowledge, this is the first instance when a patient was successfully re-treated with cisplatin after having developed PRES. The only other example in the literature is of re-treatment with bevacizumab in a patient with glioblastoma [10].

The excellent response to re-treatment without recurrence of neurological symptoms in our patient's case provides insight that the possibility of re-treatment with the offending agent may be an option in scenarios where other interventions are limited. In the field of medical oncology where curative therapeutic options may sometimes be very limited, this possibility of re-treatment could be invaluable.




Figure 2 Magnetic resonance imaging scan of the brain six weeks after initial treatment with cisplatin. The changes of posterior reversible encephalopathy syndrome have resolved in both T1-weighted and T2-weighted images **(A,B)**. The T1 post-contrast **(C)** and diffusion-weighted images **(D)** are also normal.

However, the ultimate safety of this approach will require additional evaluation.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MNZ performed the literature search and drafted the manuscript. NM conceived the case report and provided guidance for drafting the manuscript. MSM participated in its design and co-ordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Received: 19 June 2012 Accepted: 24 October 2012 Published: 29 November 2012

References

- Berman IJ, Mann MP: Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-yearold man. Cancer 1980, 45:764–766.
- Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR: A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996, 334:494–500.
- Kaplan RS, Wiernik PH: Neurotoxicity of antineoplastic drugs. Semin Oncol 1982. 9:103–130.
- Stott VL, Hurrell MA, Anderson TJ: Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J 2005, 35:83–90.
- Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA: Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010, 85:427–432.
- Kinoshita T, Moritani T, Shrier DA, Hiwatashi A, Wang HZ, Numaguchi Y, Westesson PL: Diffusion-weighted MR imaging of posterior reversible leukoencephalopathy syndrome: a pictorial essay. Clin Imaging 2003, 27:307–315.
- Covarrubias DJ, Luetmer PH, Campeau NG: Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusionweighted MR images. AJNR Am J Neuroradiol 2002, 23:1038–1048.
- Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P: Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012, 30:e76–e78.
- Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993, 11:598–606.
- Lou E, Turner S, Sumrall A, Reardon DA, Desjardins A, Peters KB, Sampson JH, Friedman HS, Vredenburgh JJ: Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol 2011, 29:e739–e742.

doi:10.1186/1752-1947-6-409

Cite this article as: Zahir *et al.*: Cisplatin-induced posterior reversible encephalopathy syndrome and successful re-treatment in a patient with non-seminomatous germ cell tumor: a case report. *Journal of Medical Case Reports* 2012 **6**:409.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

